In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
Although our approach to the clinical management of osteoporosis (OP) and degenerative joint diseases (DJD)-major causes of disability and morbidity in the elderly-has greatly advanced in the past decades, curative treatments that could bring ultimate solutions have yet to be found or developed. Effective and timely development of candidate drugs is a critical function of the availability of sensitive and accurate methodological arsenal enabling the recognition and quantification of pharmacodynamic effects. The established concept that both OP and DJD arise from an imbalance in processes of tissue formation and degradation draws attention to need of establishing in vitro, ex vivo, and in vivo experimental settings, which allow obtaining insights into the mechanisms driving increased bone and cartilage degradation at cellular, organ, and organism levels. When addressing changes in bone or cartilage turnover at the organ or organism level, monitoring tools adequately reflecting the outcome of tissue homeostasis become particularly critical. In this context, bioassays targeting the quantification of various degradation and formation products of bone and cartilage matrix elements represent a useful approach. In this review, a comprehensive overview of widely used and recently established in vitro, ex vivo, and in vivo set-ups is provided, which in many cases effectively take advantage of the potentials of biomarkers. In addition to describing and discussing the advantages and limitations of each assay and their methods of evaluation, we added experimental and clinical data illustrating the utility of biomarkers for these methodological approaches.
Schaller
S
S
Pharmos Bioscience A/S, Herlev, Denmark.
Henriksen
K
K
Hoegh-Andersen
P
P
Søndergaard
B C
BC
Sumer
E U
EU
Tanko
L B
LB
Qvist
P
P
Karsdal
M A
MA
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001681:Biological Assay / Q000379:methods; D015415:Biomarkers / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D006801:Humans; D010003:Osteoarthritis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D015415:Biomarkers